Drug Trial Radar · NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
Nov 4, 2027
Study completion Nov 4, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Conditions
- Malignant Neoplasm
Interventions
OpevesostatDrug
Tablet for oral administration.
Fludrocortisone/ Fludrocortisone acetateDrug
Tablet for oral administration.
Dexamethasone/Dexamethasone acetateDrug
Tablet for oral administration.
Rescue MedicationsDrug
Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.
FulvestrantDrug
Administered via intramuscular injection.
ExemestaneDrug
Tablet for oral administration.
Megestrol acetate/Medroxyprogesterone acetateDrug
Tablet for oral administration.
TamoxifenDrug
Tablet for oral administration.
LetrozoleDrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) - All CohortsTime frame: Up to approximately 2 years
Locations
60 sites in 13 countries. Site status is shown where the registry gives one.
Alaska Womens Cancer Care ( Site 0037)
Anchorage, Alaska · Recruiting
Mount Sinai Cancer Center ( Site 0009)
Miami Beach, Florida · Recruiting
TRIALS 365 ( Site 0022)
Shreveport, Louisiana · Recruiting
Mary Lanning Healthcare ( Site 0019)
Hastings, Nebraska · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021)
Hackensack, New Jersey · Recruiting
Rockefeller Outpatient Pavilion ( Site 0002)
New York, New York · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0008)
Columbus, Ohio · Recruiting
Baylor College of Medicine Medical Center ( Site 0004)
Houston, Texas · Recruiting
Harris Health System ( Site 0040)
Houston, Texas · Recruiting
Mays Cancer Center ( Site 0039)
San Antonio, Texas · Recruiting
Hospital Aleman ( Site 0301)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Centro Medico Dr. Doreski - Fundación Respirar ( Site 0302)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Instituto Alexander Fleming ( Site 0303)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Instituto Nacional de Câncer - INCA ( Site 3107)
Rio de Janeiro, Brazil · Recruiting
Hospital Santa Rita de Cassia ( Site 3104)
Vitória, Espírito Santo, Brazil · Recruiting
Obras Sociais Irma Dulce ( Site 3112)
Salvador, Estado de Bahia, Brazil · Recruiting
Hospital Felicio Rocho ( Site 3105)
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital de Cancer de Pernambuco ( Site 3103)
Recife, Pernambuco, Brazil · Recruiting
Liga Norte Riograndense Contra o Cancer ( Site 3108)
Natal, Rio Grande do Norte, Brazil · Recruiting
Sunnybrook Research Institute ( Site 0203)
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre ( Site 0202)
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0200)
Montreal, Quebec, Canada · Recruiting
Jewish General Hospital ( Site 0201)
Montreal, Quebec, Canada · Recruiting
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0205)
Sherbrooke, Quebec, Canada · Recruiting
Fundación Arturo López Pérez ( Site 3300)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 3307)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 3301)
Santiago, Region M. de Santiago, Chile · Recruiting
ONCOCENTRO APYS ( Site 3302)
Viña del Mar, Valparaiso, Chile · Recruiting
Pantai Hospital Kuala Lumpur ( Site 0603)
Kuala Lumpur, Malaysia · Recruiting
University Malaya Medical Centre ( Site 0601)
Kuala Lumpur, Malaysia · Recruiting
Sarawak General Hospital ( Site 0602)
Kuching, Sarawak, Malaysia · Recruiting
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 3400)
Lima, Peru · Recruiting
Instituto Nacional de Enfermedades Neoplásicas ( Site 3401)
Lima, Peru · Recruiting
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 3405)
Concepción, Departamento de Junín, Peru · Recruiting
Clínica San Antonio ( Site 3404)
Trujillo, La Libertad, Peru · Recruiting
National Cancer Centre Singapore ( Site 0800)
Singapore, Central Singapore, Singapore · Recruiting
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2001)
Madrid, Spain · Recruiting
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2000)
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2003)
A Coruña, La Coruna, Spain · Recruiting
Clinica Universitaria Navarra - Madrid ( Site 2004)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.